Publications by authors named "Annette Lam"

Claim this Profile
R
Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database.
S Vincent Rajkumar, María-Victoria Mateos, Marcy Schaeffer, Xiwu Lin, Sacheeta Bathija, Annette Lam

Blood Cancer J· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data.
Brian G M Durie, Shaji K Kumar, Eric M Ammann, Alex Z Fu, Shuchita Kaila, Annette Lam

Adv Ther· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma.
Meletios Dimopoulos, Pieter Sonneveld, Salomon Manier, Annette Lam, Tito Roccia

BMC Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the prognostic utility of hematologic response for overall survival in patients with newly diagnosed AL amyloidosis: results of a meta-analysis.
Efstathios Kastritis, Arpit Misra, Laura Gurskyte, Florint Kroi, Andre Verhoek, Annette Lam

Hematology· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies.
Viera Sandecka, Tereza Popkova, Martin Stork, Vladimir Maisnar, Jiri Minarik, Annette Lam

Blood Cancer J· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases.
Angela Dispenzieri, Jeffrey Zonder, James Hoffman, Sandra W Wong, Michaela Liedtke, Annette Lam

Amyloid· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current Health State Affected Patient Preferences More Than Disease Status: A Discrete Choice Experiment in Multiple Myeloma.
Tommi Tervonen, Ashley Duenas, Hannah Collacott, Annette Lam, Katharine S Gries

Value Health· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Treatment Sequencing on Overall Survival in Patients with Transplant-Ineligible Newly Diagnosed Myeloma.
Rafael Fonseca, Thierry Facon, Mahmoud Hashim, Sandhya Nair, Jianming He, Annette Lam

Oncologist· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma.
Jianming He, Heather Berringer, Bart Heeg, Haoyao Ruan, Tobias Kampfenkel, Annette Lam

Adv Ther· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.
Thierry Facon, Jesús San-Miguel, Meletios A Dimopoulos, Maria-Victoria Mateos, Michele Cavo, Annette Lam

Adv Ther· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.
Thierry Facon, Jesús San-Miguel, Meletios A Dimopoulos, Maria-Victoria Mateos, Michele Cavo, Annette Lam

Adv Ther· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systematic literature review of evidence in amyloid light-chain amyloidosis.
Charlene Lee, Annette Lam, Teresa Kangappaden, Pyper Olver, Sarah Kane

J Comp Eff Res· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient Perceptions Regarding Multiple Myeloma and Its Treatment: Qualitative Evidence from Interviews with Patients in the United Kingdom, France, and Germany.
Jianming He, Ashley Duenas, Hannah Collacott, Annette Lam, Katharine S Gries

Patient· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a Time and Motion Survey Regarding Subcutaneous versus Intravenous Administration of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma.
Mary Slavcev, Allison Spinelli, Elisabeth Absalon, Tara Masterson, Christoph Heuck, Annette Lam

Clinicoecon Outcomes Res· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A systematic review of noninferiority margins in oncology clinical trials.
Mahmoud Hashim, Talitha Vincken, Florint Kroi, Samron Gebregergish, Mike Spencer, Annette Lam

J Comp Eff Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D-VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant-eligible patients with newly diagnosed multiple myeloma, using propensity score matching.
Philippe Moreau, Cyrille Hulin, Sonja Zweegman, Mahmoud Hashim, Yannan Hu, Annette Lam

EJHaem· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison.
Philippe Moreau, Benjamin Hebraud, Thierry Facon, Xavier Leleu, Cyrille Hulin, Annette Lam

Immunotherapy· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myeloma.
Brian G M Durie, Shaji K Kumar, Saad Z Usmani, Bareng A S Nonyane, Eric M Ammann, Annette Lam

Am J Hematol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis.
Vania Hungria, Deborah M Martínez-Baños, María-Victoria Mateos, Meletios A Dimopoulos, Michele Cavo, Annette Lam

Adv Ther· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.
Nikhil C Munshi, Herve Avet-Loiseau, Kenneth C Anderson, Paola Neri, Bruno Paiva, Annette Lam

Blood Adv· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matching-adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible.
Pieter Sonneveld, María-Victoria Mateos, Adrian Alegre, Thierry Facon, Cyrille Hulin, Annette Lam

EJHaem· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma.
Rafael Fonseca, Saad Z Usmani, Maneesha Mehra, Mary Slavcev, Jianming He, Annette Lam

BMC Cancer· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies.
Michele Cavo, Meletios A Dimopoulos, Jesus San-Miguel, Maria-Victoria Mateos, Andrzej Jakubowiak, Annette Lam

Clin Lymphoma Myeloma Leuk· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of efficacy from two different dosing regimens of bortezomib: an exposure-response analysis.
Dolly A Parasrampuria, Jianming He, Liping Zhang, Bogdan Muresan, Peter Hu, Annette Lam

Br J Haematol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison.
Maria-Victoria Mateos, Jesus San-Miguel, Hartmut Goldschmidt, Pieter Sonneveld, Meletios A Dimopoulos, Annette Lam

Leuk Lymphoma· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis